Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry
Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry. // Clinical Colorectal Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1533002826000046?dgcid=rss_sd_all
Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry. Clinical Colorectal Cancer. https://www.sciencedirect.com/science/article/pii/S1533002826000046?dgcid=rss_sd_all
“Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry.” Clinical Colorectal Cancer.
@article{article40731,
title = {Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry},
journal = {Clinical Colorectal Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1533002826000046?dgcid=rss_sd_all}
}